The American Journal of Managed Care9 小时
Delandistrogene Moxeparvovec Fails to Meet Primary Endpoint in Phase 3 Study
Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
Eyenovia, Inc.: Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and eval ...